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SUMMARY
Neuronal autoantibodies targeting cell surface antigens
have been described in association with autoimmune
encephalitides which frequently feature psychosis and
other psychiatric disturbances alongside neurological
signs and symptoms. Little has been written however
about the long-term psychiatric status of individuals
following recovery from the acute phase of autoimmune
encephalitis, despite case series and anecdotal evidence
suggesting this may be a cause of considerable disability.
Here, we describe a man aged 58 years with no
psychiatric history who developed a severe and acute
psychotic disorder following resolution of a protracted
course of limbic encephalitis associated with antibodies
to leucine-rich glioma inactivated 1 protein. No
indications of a gross ongoing inﬂammatory or
encephalopathic process were present at presentation of
his psychosis. Possible aetiologies of his acute psychosis
are discussed. This case highlights the importance of
ongoing psychiatric follow-up of patients following an
episode of autoimmune encephalitis.
BACKGROUND
Autoimmune encephalopathy syndromes associated
with autoantibodies to the voltage-gated potassium
channel (VGKC) or its complexed proteins were
ﬁrst described in 2001.1 Subsequently, the spectrum
of neurological disorders associated with VGKC
complex antibodies has expanded considerably to
encompass multiple central and peripheral nervous
system manifestations.2 However, in some cases,
VGKC complex antibodies, particularly when
present at low titre, may not be pathogenic.3
In 2010, the receptor-associated proteins like
contactin-associated protein-like 2 (CASPR2) and
leucine-rich glioma inactivated 1 (LGI1) were iden-
tiﬁed as the antigenic targets in most cases of
VGKC antibody-associated syndromes.4 The
most characteristic syndrome is limbic encephalitis,
frequently featuring confusion, memory impair-
ment, psychiatric symptoms and seizures.5 LGI1
antibody-associated encephalitis is frequently pre-
ceded by a highly characteristic seizure semiology
termed ‘faciobrachial dystonic seizures’.5
VGKC antibodies that do not have LGI1 or
CASPR2 as their target antigen have recently been
identiﬁed as having largely intracellular targets,
making their pathogenicity unlikely.6
Case reports of individuals with VGKC complex
autoantibodies with predominantly psychiatric pre-
sentations have been published and VGKC complex
autoantibodies have recently been identiﬁed in a
proportion of all individuals presenting to psychi-
atric services with psychosis.7–9
The outcome of VGKC complex-associated
limbic encephalitis is variable and shows some
antigen speciﬁcity: LGI1 encephalitis is associated
with greater cognitive deﬁcits and rates of hippo-
campal atrophy than CASPR2 encephalitis.10
Although the natural history of the disease is likely
to be self-limiting if left untreated with immuno-
therapy,11 and the extent of cognitive deﬁcits can
be limited by early initiation of immunother-
apy;12 13 only around one-third of patients recover
their baseline cognitive function.14 Relapse of LGI1
encephalitis occurs in 35% of patients, sometimes
as long as 8 years after initial presentation.15
The published data on long-term psychiatric
outcome following VGKC complex-associated
limbic encephalitis generally, or LGI1 encephalitis
more speciﬁcally, are scant but suggests that there
may be signiﬁcant residual psychiatric symptoms
and that de novo psychiatric features, including
anxiety and affective and impulse-control disorders,
may develop.16
CASE PRESENTATION
In August 2013, a right-handed man aged 57 years
was admitted to hospital with a week’s history of
confusion, personality change and a witnessed gen-
eralised tonic–clonic seizure. For 4 months before
the admission, he had been noted by his wife to be
chanting in his sleep; the chants made reference to
death and dying. Nocturnal arm twitching was
noted for 2 months before admission and leg
muscle twitching had been noted for about a year.
His medical history was notable for degenerative
lumbar canal stenosis treated by surgical decom-
pression in 2010, which was complicated by a
dural tear and infection. He had a family history of
Cowden syndrome.
In the ward, he had three further generalised sei-
zures. An MRI brain revealed left medial temporal
lobe inﬂammatory changes. Cerebrospinal ﬂuid
(CSF) analysis showed lymphocytosis (lymphocyte
count 10, polymorphonuclear neutrophil count 0,
red cell count 334, protein 1.03 g and glucose 3.9).
CSF PCR for herpes simplex virus was sent but,
unfortunately, lost. He was treated empirically with
acyclovir, ceftriaxone and levetiracetam with
improvement and was discharged home.
Two to 3 weeks after discharge, his condition
began to deteriorate, with worsening memory, visual
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hallucinations, delusions of persecution by unknown assailants,
continued nocturnal chanting and frequent déjà vu. He would
put metal cutlery into the toaster and walk off into busy roads.
He was noted to have brief paroxysmal movements involving his
neck and arms. By 3 months after initial presentation, he required
constant supervision. Test for VGKC complex antibodies on a
serum sample taken on the initial admission returned positive
with a titre of 1834 pmol/L. He was readmitted to hospital.
Examination was notable for disorientation to place, echopraxia
and bilateral weak ankle dorsiﬂexion (a sequel of lumbar canal
stenosis). He was hyponatraemic.
INVESTIGATIONS
The following were negative: ANA, ANCA, ENA, anti-GAD anti-
bodies, HIV I and II antibodies, hepatitis B and C and syphilis ser-
ology tumour markers (AFP, CEA and CA199). The VGKC
complex antibody titre had risen to 8310 pmol/L (ﬁgure 1). A
scrotal ultrasound scan and a CTof the chest, abdomen and pelvis
revealed no malignancy. A repeat MRI brain showed abnormal
T2/FLAIR hyperintensity in the left caudate, anterior putamen
and insula with mild swelling. Prolonged EEG showed generalised
slowing with frequent subclinical seizures bilaterally and one sec-
ondary generalised seizure. The twitching episodes in sleep were
not associated with abnormal EEG correlates. He was conﬁrmed
by staff to be experiencing clinical faciobrachial dystonic seizures
as well as generalised tonic–clonic seizures. Subsequent analysis,
in 2016, of his ﬁrst VGKC complex antibody-positive serum
sample was positive for LGI1 antibodies.
TREATMENT
He received 3 days intravenous methylprednisolone followed by
plasma exchange and 5 days intravenous immunoglobulins for
presumed LGI1 antibody-mediated encephalitis. Levetiracetam
was switched to zonisamide and sodium valproate. He made a
signiﬁcant recovery with cessation of observable seizures and
was discharged home on a reducing course of prednisolone at
an initial dose of 60 mg daily.
OUTCOME AND FOLLOW-UP
Six months after presentation, he underwent neuropsychological
testing, which highlighted signiﬁcantly impaired verbal memory
(1st centile) and below-expected performance on processing
speed and executive function. His community rehabilitation
team described a slow functional recovery and made note of
moderate anxiety and depressive symptoms.
Seven months after initial presentation, he was readmitted for
recurrent seizures and increasing confusion. His prednisolone dose
at the time had been tapered to 30 mg daily. The VGKC complex
antibody titre was 1050 pmol/L. He was treated with intravenous
methylprednisolone 500 mg once daily for 3 days followed by
plasma exchange and then pulsed intravenous cyclophosphamide
(15 mg/kg weekly at time 0, 2 and 4 weeks). He was assessed by
the neuropsychiatry team who noted there was no psychosis. He
required intensive rehabilitation input and was eventually dis-
charged in August 2014, a year after initial presentation.
Five months later (∼17 months after presentation), he was
noted by his neuropsychiatry team to be experiencing visual hal-
lucinations, aggressive outbursts, paranoid ideas and the belief
that in the past he had been infected by many small creatures
called ‘mots’ who had been sent by a shadowy man in black and
were eating him from the inside of his body. It was reported by
his family that these symptoms had been ongoing for 2 months.
Over the following days, his paranoid behaviour and aggression
to his family worsened and he was readmitted to hospital
for investigation of a presumed relapse of encephalitis.
On admission, he was fully alert and orientated and no new
Figure 1 Voltage-gated potassium channel antibody titre: relation to neuropsychiatric symptoms and treatment. (a) Onset of leg muscle
‘twitching’; (b) onset of nocturnal behavioural disturbance; (c) onset of ﬂorid encephalopathy, including confusion, hallucinations and seizures;
(d) discharge from hospital with resolving confusion, seizure freedom; (e) onset of severe, acute psychosis; (f ) recovery from acute psychosis on
antipsychotic medication. *LGI1 antibody positive; #intravenous immunoglobulins and plasma exchange started; +cyclophosphamide started.
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neurological signs or seizures were noted. He became increas-
ingly agitated and expressed persecutory ideas about hospital
staff, refusing to eat and drink in the belief that food and ﬂuid
had been poisoned.
EEG was within normal limits and MRI showed an atrophic
left hippocampus with no new inﬂammatory changes. Serum
VGKC complex antibodies were negative.
Owing to worsening psychosis and increasing risk, he was
admitted to a psychiatric ward where he initially required inten-
sive 1:1 nursing. He was noted to be paranoid, grandiose
(expressing delusions of wealth and plans to ‘ﬁx’ the National
Health Service) and tangential with aggressive outbursts. He
was started on risperidone and regular benzodiazepines and his
psychotic symptoms improved over the following weeks. After
a 2-month admission, he had made a full recovery and he was
discharged on risperidone 4 mg.
He has ongoing cognitive difﬁculties and he and his carer
describe prominent apathy, with occasional nightmares and
health-related anxiety. He remains under the care of a commu-
nity mental health team and has had no recurrence of any
psychotic symptoms on a reducing dose of risperidone (cur-
rently 3 mg), ﬂuoxetine 20 mg and low-dose benzodiazepines.
DISCUSSION
This is the ﬁrst description of a de novo psychotic illness devel-
oping following autoimmune encephalitis in a patient with no
previous psychiatric history. VGKC complex autoantibody-
associated encephalitis commonly presents with psychotic and
confusional symptoms as part of a wider constellation of psychi-
atric and neurological symptoms,17 as it did in the current case.
Remarkably, however, VGKC complex antibodies were subse-
quently undetectable during a severe psychotic deterioration
characterised by agitation, persecutory delusions, grandiosity
and thought disorder but no concurrent confusion. MRI and
EEG did not support an ongoing encephalitic process.
Possible aetiologies for the acute psychotic episode include:
(1) pathogenic antibodies being present in CSF but not in serum
(ie, atypical relapse of LGI1 encephalitis); (2) a manifestation of
other postencephalitic neurological changes; or (3) a response
to the stress of illness.
We consider an atypical relapse of LGI1 encephalitis to be
unlikely, given the swift resolution of his psychosis with anti-
psychotic treatment and the lack of any neurological symptoms
or paraclinical evidence of current encephalitis. Further, analysis
of paired serum-CSF samples suggests intrathecal synthesis is
rare in encephalitis associated with antibodies to the VGKC
complex.18
Given mounting evidence for the use of positron emission
tomography (PET) in the assessment of autoimmune encephal-
itis,19–21 it is possible that PET may have a future role in the
assessment of cases such as this, where demonstration of contin-
ued hypermetabolic activity, even in the absence of positive
MRI and EEG ﬁndings, could indicate ongoing inﬂammation.
Postencephalitic psychosis has been described before22 but
not in association with autoimmune encephalitis. It is likely,
however, that many cases of what in the past was called ‘idio-
pathic’ (or even ‘viral’) encephalitis may have autoimmune aeti-
ologies.23 At an epidemiological level, autoimmune diseases
associated with brain-reactive autoantibodies increase the risk of
the subsequent development of non-affective psychoses and
bipolar disorder.24 We therefore consider it likely that his psych-
osis was aetiologically related to his autoimmune encephalitis,
perhaps in a manner analogous to postencephalitic epilepsy,
although the mechanism remains unclear. Notably, hippocampal
volume loss is a consistently identiﬁed vulnerability factor for
non-organic psychosis.25 To this extent, the initial delay in diag-
nosis and treatment may have been a factor in his outcome and
possibly the development of psychosis.
The patient had a strong family history of Cowden syndrome
but had not been tested himself. The syndrome is caused by a
dominant mutation in the PTEN tumour suppressor gene and
typically manifests with malignancy and cutaneous manifesta-
tions. No malignancy was found in the patient as part of his
initial workup following his initial presentation with LGI1
encephalitis, although he did have a number of cutaneous mani-
festations typical of Cowden syndrome. PTEN mutations are
associated with an increased liability to autoimmune disorders,
although have not to date been described in association with
autoimmune encephalitis.
This case report demonstrates the importance of monitoring
for de novo psychiatric symptoms following resolution of auto-
immune encephalitis. Systematic collection of data relating to
the mental health of this group is urgently required. In combin-
ation with the evidence for persistent psychiatric and cognitive
sequelae in the postacute phase,16 we consider that psychiatric
follow-up ought to be the norm rather than the exception in
cases of autoimmune encephalitis.
Learning points
▸ Clinicians should have a high index of suspicion for an
autoimmune aetiology in patients with an encephalopathic
presentation, particularly those in whom an initial infective
workup is negative.
▸ Leucine-rich glioma inactivated 1 (LGI1) antibody
encephalitis can present with unusual behaviours including
psychotic symptoms, usually together with neurological
symptoms including seizures. Faciobrachial dystonic seizures
are highly characteristic of the disease.
▸ Recovery from LGI1 antibody encephalitis can be protracted
and may require multiple immunotherapies. Cognitive
deﬁcits following recovery are common and relapses occur in
a third of patients, mandating ongoing neurological
follow-up.
▸ Patients with this and other autoimmune encephalitides
should be followed-up psychiatrically as new-onset
psychiatric disorders, including psychosis, may occur and can
be severe.
▸ Differentiating ongoing encephalitis from new-onset
psychiatric disorder can be challenging but is essential to
guide appropriate choice of treatment.
Acknowledgements The authors would like to thank Professor Angela Vincent
and Dr Paul Shotbolt for their valuable comments and insights.
Contributors Patient care and follow-up was under the care of NM, who
conceived the case report. TP wrote the ﬁrst draft of the report, produced the ﬁgures
and liaised with the patient and family.
Funding Wellcome Trust. Grant number (105758/Z/14/Z).
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
Pollak TA, Moran N. BMJ Case Rep 2017. doi:10.1136/bcr-2016-218328 3
Unexpected outcome ( positive or negative) including adverse drug reactions
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients
with reversible limbic encephalitis. Ann Neurol 2001;50:73–8.
2 Irani SR, Gelfand JM, Al-Diwani A, et al. Cell-surface central nervous system
autoantibodies: clinical relevance and emerging paradigms. Ann Neurol
2014;76:168–84.
3 Paterson RW, Zandi MS, Armstrong R, et al. Clinical relevance of positive
voltage-gated potassium channel (VGKC)-complex antibodies: experience from a
tertiary referral centre. J Neurol Neurosurg Psychiatr 2014;85:625–30.
4 Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium
channel-complex proteins leucine-rich, glioma inactivated 1 protein and
contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and
acquired neuromyotonia. Brain 2010;133:2734–48.
5 Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1
antibody limbic encephalitis. Ann Neurol 2011;69:892–900.
6 Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of
voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatr
2017.
7 Zandi MS, Irani SR, Lang B, et al. Disease-relevant autoantibodies in ﬁrst episode
schizophrenia. J Neurol 2011;258:686–8.
8 Endres D, Perlov E, Baumgartner A, et al. Immunological ﬁndings in psychotic
syndromes: a tertiary care hospital’s CSF sample of 180 patients. Front Hum
Neurosci 2015;9:476.
9 Lennox BR, Palmer-Cooper EC, Pollak T, et al. Prevalence and clinical characteristics
of serum neuronal cell surface antibodies in ﬁrst-episode psychosis: a case-control
study. Lancet Psychiatry 2017;4:42–8.
10 Malter MP, Frisch C, Schoene-Bake JC, et al. Outcome of limbic encephalitis with
VGKC-complex antibodies: relation to antigenic speciﬁcity. J Neurol
2014;261:1695–705.
11 Szots M, Marton A, Kover F, et al. Natural course of LGI1 encephalitis: 3–5 years of
follow-up without immunotherapy. J Neurol Sci 2014;343:198–202.
12 Finke C, Prüss H, Heine J, et al. Evaluation of cognitive deﬁcits and structural
hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1
antibodies. JAMA Neurol 2017;74:50–9.
13 Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the inﬂuence of
immunotherapy on seizure control and prevention of cognitive impairment in a
broadening phenotype. Brain 2013;136(Pt 10):3151–62.
14 Ariño H, Armangué T, Petit-Pedrol M, et al. Anti-LGI1-associated cognitive
impairment: presentation and long-term outcome. Neurology 2016;87:759–65.
15 van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: clinical
syndrome and long-term follow-up. Neurology 2016;87:1449–56.
16 Sarkis RA, Nehme R, Chemali ZN. Neuropsychiatric and seizure outcomes
in nonparaneoplastic autoimmune limbic encephalitis. Epilepsy Behav
2014;39:21–5.
17 Somers KJ, Lennon VA, Rundell JR, et al. Psychiatric manifestations of voltage-gated
potassium-channel complex autoimmunity. J Neuropsychiatry Clin Neurosci
2011;23:425–33.
18 Malter MP, Elger CE, Surges R. Diagnostic value of CSF ﬁndings in
antibody-associated limbic and anti-NMDAR-encephalitis. Seizure 2013;22:
136–40.
19 Newey CR, Sarwal A, Hantus S. [(18)F]-ﬂuoro-deoxy-glucose positron emission
tomography scan should be obtained early in cases of autoimmune encephalitis.
Autoimmune Dis 2016;2016:9450452.
20 Baumgartner A, Rauer S, Mader I, et al. Cerebral FDG-PET and MRI ﬁndings in
autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol
2013;260:2744–53.
21 Morbelli S, Djekidel M, Hesse S, et al. Neuroimaging Committee of the European
Association of Nuclear M. Role of (18)F-FDG-PET imaging in the diagnosis of
autoimmune encephalitis. Lancet Neurol 2016;15:1009–10.
22 Davison K, Bagley CR. Schizophrenia-like psychoses associated with organic
disorders of the central nervous system: a review of the literature. In: Herrington
RN, ed. Current problems in neuropsychiatry, Part II. British Journal of
Psychiatry Special Publication No. 4. Ashford, Kent: Headley Brothers,
1969:113–83.
23 Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences
in their clinical presentations in England: a multicentre, population-based
prospective study. Lancet Infect Dis 2010;10:835–44.
24 Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk
factors for schizophrenia. Ann N Y Acad Sci 2012;1262:56–66.
25 Fusar-Poli P, Borgwardt S, Crescini A, et al. Neuroanatomy of vulnerability
to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev
2011;35:1175–85.
Copyright 2017 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit
http://group.bmj.com/group/rights-licensing/permissions.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.
Become a Fellow of BMJ Case Reports today and you can:
▸ Submit as many cases as you like
▸ Enjoy fast sympathetic peer review and rapid publication of accepted articles
▸ Access all the published articles
▸ Re-use any of the published material for personal use and teaching without further permission
For information on Institutional Fellowships contact consortiasales@bmjgroup.com
Visit casereports.bmj.com for more articles like this and to become a Fellow
4 Pollak TA, Moran N. BMJ Case Rep 2017. doi:10.1136/bcr-2016-218328
Unexpected outcome ( positive or negative) including adverse drug reactions
